Scintillation proximity assay (SPA) as a new approach to determine a ligand’s kinetic profile. A case in point for the adenosine A1 receptor

Purinergic Signalling

Volumn 12, Issue 1, 2016, Pages 115-126

  Xia, Lizi ^a   de Vries, Henk ^a   IJzerman, Ad P ^a   Heitman, Laura H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adenosine A1 receptor; Binding kinetics; G protein coupled receptors; Residence time; Scintillation proximity assay

Indexed keywords

ADENOSINE A1 RECEPTOR; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; LIGAND; XANTHINE DERIVATIVE;

ANALYTICAL PARAMETERS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CHO CELL LINE; CONTROLLED STUDY; DISSOCIATION RATE CONSTANT; FILTRATION; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN INTERACTION; RADIOASSAY; SCINTILLATION PROXIMITY ASSAY; SCINTISCANNING; ANIMAL; BINDING COMPETITION; CELL MEMBRANE; CHEMISTRY; CRICETULUS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HAMSTER; KINETICS; METABOLISM;

ADENOSINE A1 RECEPTOR ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; FILTRATION; HUMANS; KINETICS; LIGANDS; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A1; RECEPTORS, G-PROTEIN-COUPLED; XANTHINES;

EID: 84957939363     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-015-9485-0     Document Type: Article

References (37)

1. Harder D, Fotiadis D (2012) Measuring substrate binding and affinity of purified membrane transport proteins using the scintillation proximity assay. Nat Protoc 7(9):1569–1578
2. Glickman JF, Schmid A, Ferrand S (2008) Scintillation proximity assays in high-throughput screening. Assay Drug Dev Technol 6(3):433–455
3. Bosworth N, Towers P (1989) Scintillation proximity assay. Nature 341(6238):167–168
4. Hart HE, Greenwald EB (1979) Scintillation-proximity assay of antigen—antibody binding kinetics: concise communication. J Nucl Med 20(10):1062–1065
5. Udenfriend S, Gerber LD, Brink L, Spector S (1985) Scintillation proximity radioimmunoassay utilizing 125I-labeled ligands. Proc Natl Acad Sci U S A 82(24):8672–8676
6. Heise CE, Sullivan SK, Crowe PD (2007) Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen 12(2):235–239
7. Swinney DC, Beavis P, Chuang K-T, Zheng Y, Lee I, Gee P, Deval J, Rotstein DM, Dioszegi M, Ravendran P, Zhang J, Sankuratri S, Kondru R, Vauquelin G (2014) A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Brit J Pharmacol 171(14):3364–3375
8. Chao J, Taveras AG, Chao J, Aki C, Dwyer M, Yu Y, Purakkattle B, Rindgen D, Jakway J, Hipkin W, Fosetta J, Fan X, Lundell D, Fine J, Minnicozzi M, Phillips J, Merritt JR (2007) C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorg Med Chem Lett 17(13):3778–3783
9. Mikami T, Ochi Y, Suzuki K, Saito T, Sugie Y, Sakakibara M (2008) 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-α]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs. J Pharmacol Exp Ther 325(1):190–199
10. Auld DS Farmen MW, Kahl SD et al (2012) Receptor binding assays for HTS and drug discovery, Assay Guidance Manual [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda
11. Tummino PJ, Copeland RA (2008) Residence time of receptor—ligand complexes and its effect on biological function. Biochemistry 47(20):5481–5492
12. Guo D, Hillger JM, IJzerman AP, Heitman LH (2014) Drug-target residence time—a case for G protein-coupled receptors. Med Res Rev 34(4):856–892
13. Sykes DA, Dowling MR, Charlton SJ (2009) Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76(3):543–551
14. Guo D, Mulder-Krieger T, IJzerman AP, Heitman LH (2012) Functional efficacy of adenosine A(2A) receptor agonists is positively correlated to their receptor residence time. Brit J Pharmacol 166(6):1846–1859
15. Vilums M, Zweemer AJM, Yu Z, de Vries H, Hillger JM, Wapenaar H, Bollen IAE, Barmare F, Gross R, Clemens J, Krenitsky P, Brussee J, Stamos D, Saunders J, Heitman LH, IJzerman AP (2013) Structure-kinetic relationships—an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists. J Med Chem 56(19):7706–7714
16. Guo D, Xia L, van Veldhoven JPD, Hazeu M, Mocking T, Brussee J, IJzerman AP, Heitman LH (2014) Binding kinetics of ZM241385 derivatives at the human adenosine A2A receptor. ChemMedChem 9(4):752–761
17. van Veldhoven JPD, Liu R, Thee SA, Wouters Y, Verhoork SJM, Mooiman C, Louvel J, IJzerman AP (2015) Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists. Bioorgan Med Chem 23(14):4013–4025
18. Motulsky HJ, Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25(1):1–9
19. Morriello GJ, Chicchi G, Johnson T, Mills SG, DeMartino J, Kurtz M, Tsao KLC, Zheng S, Tong X, Carlson E, Townson K, Wheeldon A, Boyce S, Collinson N, Rupniak N, DeVita RJ (2010) Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor. Bioorg Med Chem Lett 20(19):5925–5932
20. Ehlert FJ, Roeske WR, Yamamura HI (1981) Mathematical analysis of the kinetics of competitive inhibition in neurotransmitter receptor binding assays. Mol Pharmacol 19(3):367–371
21. Guo D, Dorp EJH, Mulder-Krieger T, Veldhoven JPD, Brussee J, IJzerman AP, Heitman LH (2013) Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen 18(3):309–320
22. Berry J, Price-Jones M, Killian B. (2012) Use of scintillation proximity assay to measure radioligand binding to immobilized receptors without separation of bound from free ligand. In: Davenport AP (Ed.) Receptor Binding Techniques, vol 897. Methods in Molecular Biology. Humana Press, pp 79–94.
23. Martinson EA, Johnson RA, Wells JN (1987) Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. Mol Pharmacol 31(3):247–252
24. Muijlwijk-Koezen JEV, Timmerman H, der Sluis RP, van de Stolpe AC, Menge WMPB, Beukers MW, van der Graaf PH, de Groote M, IJzerman AP (2001) Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a ‘receptor knock-down’ tool. Bioorg Med Chem Lett 11(6):815–818
25. Klotz K-N, Lohse M, Schwabe U, Cristalli G, Vittori S, Grifantini M (1989) 2-Chloro-N6-[3H]cyclopentyladenosine ([3HCCPA)—a high affinity agonist radioligand for A1 adenosine receptors. N-S Arch Pharmacol 340(6):679–683
26. Cusack NJ, Hourani SMO (1981) 5′-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Brit J Pharmacol 72(3):443–447
27. Beukers MW, Chang LCW, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Brussee J, IJzerman AP (2004) New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 47(15):3707–3709
28. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150(1):76–85
29. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23):3099–3108
30. Hoffmann C, Castro M, Rinken A, Leurs R, Hill SJ, Vischer HF (2015) Ligand residence time at GPCRs—why we should take our time to study it. Mol Pharmacol. doi:10.1124/mol.115.099671
31. Horrocks D (1974) Scintilation solutions. In: Applications of liquid scintillation counting. Academic, New York, pp 35–68
32. Horrocks D (1974) Liquid scintillation counters and multiplier phototubes. In: Applications of liquid scintillation counting. Academic, New York, pp 69–89
33. Kahl SD, Sittampalam GS, Weidner J (2012) Calculations and Instrumentation used for Radioligand Binding Assays. Assay Guidance Manual [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda
34. Segala E, Errey JC, Fiez-Vandal C, Zhukov A, Cooke RM (2015) Biosensor-based affinities and binding kinetics of small molecule antagonists to the adenosine A2A receptor reconstituted in HDL like particles. FEBS Lett 589(13):1399–1405
35. Bocquet N, Kohler J, Hug MN, Kusznir EA, Rufer AC, Dawson RJ, Hennig M, Ruf A, Huber W, Huber S (2015) Real-time monitoring of binding events on a thermostabilized human A2A receptor embedded in a lipid bilayer by surface plasmon resonance. BBA - Biomembranes 1848(5):1224–1233
36. Zheng W, Carroll SS, Inglese J, Graves R, Howells L, Strulovici B (2001) Miniaturization of a hepatitis C virus RNA polymerase assay using a −102°C cooled CCD camera-based imaging system. Anal Biochem 290(2):214–220
37. Bryant R, McGuinness D, Turek-Etienne T, Guyer D, Yu L, Howells L, Caravano J, Zhai Y, Lachowicz J (2004) WGA-coated yttrium oxide beads enable an imaging-based adenosine 2a receptor binding scintillation proximity assay suitable for high throughput screening. Assay Drug Dev Technol 2(3):290–299